Carl Regillo, MD - Clinical Colloquia in Retinal Disease: Updating Evidence-Based, Patient-Centered Care for Diabetic Retinopathy

PeerView Endocrinology & Diabetes CME/CNE/CPE Audio Podcast

Go online to PeerView.com/CMG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Intravitreal treatments have advanced rapidly to become the mainstay of therapy for DR/DME. Anti-VEGF agents and corticosteroid implants have demonstrated efficacy for reducing vision loss from DR/DME and may be administered adjunctively to laser photocoagulation. Increasingly, studies comparing these treatments in combination, in sequence, or in head-to-head trials are becoming available, helping to refine decisions regarding the right therapy for the right patient at the right time. Additionally, new intravitreal treatments offer the potential of even higher efficacy, greater safety, or longer intervals between retreatments. Join our panel of noted retina specialists for an engaging discussion of emerging agents, including a review of recent reported clinical trials and their implications for advancing patient-centered care for DR/DME. The expert dialogue will be complemented by noteworthy insights from a patient with DR/DME who will share her personal insights on diagnosis and treatment. This three-part activity is divided into multiple chapters for ease of navigation and access: Part 1. Great Expectations: What Are We Asking of Patients Undergoing DR/DME Treatment?, Part 2. Seeking a Higher Standard of Care: Advances in Therapy for DR/DME, Part 3. Patient Considerations and Newer Therapies: The Practical Side of Advances in Therapy for DR/DME. Upon completion of this activity, participants should be better able to: Describe challenges associated with current intravitreal treatment regimens for DR/DME from the patient perspective, Differentiate the benefits and limitations of current and emerging intravitreal agents for the treatment of DR/DME, Evaluate the evidence for current and emerging intravitreal agents to prevent vision-threatening outcomes in patients with DR/DME, Incorporate a personalized, patient-centered approach to the use of intravitreal therapies in patients with DR/DME.